How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?

Birgitte K. Giersing*, Chad K. Porter, K. Kotloff, Pieter Neels, Alejandro Cravioto, Calman A. MacLennan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Controlled Human Infection Models (CHIMs) now exist for several infectious diseases. CHIMs offer significant insight into disease pathogenesis, as well the potential to rapidly test clinical proof-of-concept of vaccine candidates. The application of CHIMs to identify a correlate of protection that may reduce the sample size of, or obviate the need for clinical efficacy studies to achieve licensure is of considerable interest to vaccine developers and public health stakeholders. This topic was the subject of a workshop at the 2018 Vaccines Against Shigella and ETEC (VASE) conference, in the context of O-antigen-based Shigella vaccines.

Original languageEnglish
Pages (from-to)4778-4783
Number of pages6
JournalVaccine
Volume37
Issue number34
DOIs
StatePublished - 7 Aug 2019
Externally publishedYes

Keywords

  • Challenge
  • Development
  • Policy
  • Shigella
  • Vaccine

Fingerprint

Dive into the research topics of 'How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?'. Together they form a unique fingerprint.

Cite this